Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Clinical Phase 1 Study Investigating ACI-3024 for the Treatment of Alzheimer's Disease

Trial Profile

A Clinical Phase 1 Study Investigating ACI-3024 for the Treatment of Alzheimer's Disease

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ACI 3024 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 20 Sep 2019 According to an AC Immune media release, company will receive the first milestone payment of CHF30 million from Eli Lilly and Company on or before October 7, 2019 follows initiation of this study.
    • 17 Jul 2019 According to an AC Immune media release, the first patient has been dosed for this study.
    • 17 Jul 2019 Status changed from planning to recruiting, according to an AC Immune media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top